Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from ImmuPharma ( (GB:IMM) ) is now available.
ImmuPharma PLC has announced the posting of its Notice of Annual General Meeting (AGM) and Annual Report and Accounts for the year ended December 31, 2024, to its shareholders. The AGM is scheduled for June 12, 2025, at The Malmaison Hotel in London. This announcement is a routine part of the company’s governance and provides shareholders with essential information regarding the company’s financial performance and strategic direction.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. Its portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives, with a lead program, P140, targeting Systemic Lupus Erythematosus (SLE) and Chronic Idiopathic Demyelinating Polyneuropathy (CIDP).
Average Trading Volume: 3,116,513
Technical Sentiment Signal: Buy
Current Market Cap: £14.97M
For an in-depth examination of IMM stock, go to TipRanks’ Stock Analysis page.